Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

Pituitary Tumors Clinical Trial

Official title:

Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05634655
• Other study ID #: 2021-0765
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: January 1, 2025

Study information

• Verified date: December 2021
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Wu Qun
• Phone: 13605810393
• Email: 2192010[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: January 1, 2025
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• 1) histologically confirmed PAs, 2) Non-function pituitary adenomas

Exclusion Criteria:

• 1) Associated with other tumors or serious underlying diseases, 2) the medical records were not complete, or the follow-up data were missing.

Related Conditions & MeSH terms

• Pituitary Diseases
• Pituitary Neoplasms
• Pituitary Tumors

Intervention

Other:
• no interventions between two groups
no interventions between two groups

Locations

Country	Name	City	State
China	2ndAffiliated Hospital, School of Medicine	Hanzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Residual tumor size	Tumor size was evaluated by postoperative MRI	1 week after surgery
Primary	tumor recurrence	During the follow-up, the tumor recurrence was observed closely	three years